NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--Jan. 26, 2006--BrainStorm Cell Therapeutics (OTCBB:BCLI), the developer of NurOwn(TM) bone marrow derived stem cell therapeutic products for the treatment of neurodegenerative diseases, announced today that a patent application has been filed with the US Patent and Trademark Office for a new procedure to derive oligodendrocyte-like cells. The invention involves inducing oligodendrocyte-like cells using the company’s proprietary bone marrow derived human mesenchymal stem cell technology.
